Steatosis News and Research

RSS

Palmatine improved fatty liver markers in a preclinical type 2 diabetes study

Researchers used a bioinformatics-plus-rat-model approach to investigate how palmatine may help treat T2DM-associated MASLD, identifying five core targets: ADRB2, BCL3, EGR1, FOS, and MAP3K8. In rats, palmatine improved liver injury, inflammation, oxidative stress, glycolipid metabolism, steatosis, and fibrosis, while reducing apoptosis-related signaling, providing a preclinical foundation for further therapeutic study.

23 Mar 2026

Expert consensus validates UDFF for noninvasive fatty liver assessment

As the global burden of obesity, type 2 diabetes, and metabolic syndrome continues to rise, fatty liver disease has become one of the most prevalent chronic liver conditions worldwide. Its progressive forms, including metabolic dysfunction‐associated steatohepatitis (MASH), cirrhosis, and hepatocellular carcinoma, now represent a major public health challenge.

17 Mar 2026

Low testosterone and high fructose intake can worsen fatty liver disease

Low testosterone in itself can cause a variety of health problems, but the addition of a poor diet can exacerbate certain conditions. Metabolic dysfunction-associated steatotic liver disease (MASLD) is one example that approximately 40% of adult men worldwide currently suffer from and has become a global problem.

11 Mar 2026

EVA1A regulates fatty acid transporter CD36 in fatty liver disease

Metabolic Dysfunction-Associated Steatotic Liver Disease（MASLD） is characterized by excessive accumulation of lipids in hepatocytes and is closely associated with the rapid rise in insulin resistance, obesity, and diabetes prevalence, making it one of the most common chronic liver diseases worldwide.

9 Mar 2026

Women face higher liver fibrosis risk from cardiometabolic factors than men

Women with certain cardiometabolic risk factors, including type 2 diabetes and high waist circumference, face a greater increase in risk for liver fibrosis than men with the same risk factors.

9 Mar 2026

How are GLP-1 drugs reshaping treatment for obesity, diabetes, and heart disease?

A comprehensive Lancet review synthesizes evidence from major clinical trials showing that GLP-1 receptor agonists and next-generation incretin therapies deliver substantial weight loss while reducing cardiovascular and kidney risks. Emerging dual, triple, and oral agents may further expand treatment options and improve outcomes across obesity, type 2 diabetes, and related metabolic diseases.

3 Mar 2026

Study explores whether a bidirectional causal link exists between MASLD and sarcopenia

Metabolic dysfunction-associated steatotic liver disease (MASLD) and sarcopenia frequently coexist, yet their causal relationship and underlying mechanisms remain poorly defined.

13 Feb 2026

Unraveling liver injury mechanisms in familial hypobetalipoproteinemia

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and APOB.

24 Jan 2026

New study identifies the optimal exercise dose for reducing hepatic steatosis

Hepatic steatosis is a core pathological feature of metabolic dysfunction-associated steatotic liver disease (MASLD). It not only drives disease progression to intrahepatic conditions such as cirrhosis but also elevates the incidence and mortality risk of cardiovascular diseases and extrahepatic malignancies.

23 Jan 2026

Alterations in liver metabolism experienced by individuals with Down syndrome

Researchers at the University of Colorado Anschutz Linda Crnic Institute for Down Syndrome (Crnic Institute) have uncovered compelling evidence that individuals with Down syndrome experience significant alterations in liver metabolism, including elevated levels of bile acids in the bloodstream and other biomarkers of liver dysfunction.

22 Jan 2026

Preclinical study reveals potential new treatment for severe liver fibrosis

Researchers at McMaster University are leading preclinical studies into a novel drug candidate developed by Espervita Therapeutics that has the potential to prevent and reverse liver fibrosis - a dangerous, disease-induced build-up of scar tissue in the liver that often leads to cancer.

13 Jan 2026

Understanding leptin's dual function in MAFLD pathogenesis

Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a predominant chronic liver condition globally, intricately linked with obesity, type 2 diabetes (T2DM), and metabolic syndrome.

14 Nov 2025

Genetic and cellular mechanisms underlying steatotic liver disease

Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology.

10 Nov 2025

Study aims to examine the association between arsenic exposure and MASLD

While metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with obesity, the cause of its rapidly rising prevalence is not well understood.

29 Oct 2025

E2F2 protein identified as potential therapeutic target to prevent metabolic fatty liver disease progression

An international collaborative study has identified the E2F2 protein as a potential new therapeutic target to prevent metabolic fatty liver disease from progressing towards more serious conditions, such as cirrhosis or liver cancer.

22 Oct 2025

Groundbreaking 3D dynamic cell co-culture models simulate MASLD progression

In a recent work published in BME Frontiers, a collaborative study by researchers from Griffith University, Queensland University of Technology, University of Queensland, and Nanjing Stomatological Hospital has introduced groundbreaking three-dimensional (3D) dynamic cell co-culture models to simulate metabolic dysfunction-associated steatotic liver disease (MASLD) progression stages.

22 Oct 2025

Ganoderma lucidum protects against liver damage from high-fat diets

A long-term high-fat diet (HFD) exerts lipotoxic effects on multiple organs, particularly the liver, leading to metabolic diseases.

16 Oct 2025

Study links gut dysbiosis with severe steatosis in MASLD

A new study in eGastroenterology links gut dysbiosis with severe steatosis in metabolic dysfunction–associated steatotic liver disease (MASLD).

15 Oct 2025

Higher arsenic exposure linked to increased risk of metabolic liver disease

While metabolic dysfunction-associated steatotic liver disease (MASLD) is associated with obesity, the cause of its rapidly rising prevalence is not well understood. In this study, we aimed to examine the association between arsenic exposure and MASLD in humans.

22 Sep 2025

CHI3L1 emerges as a powerful biomarker for liver disease diagnosis and management

The identification of Chitinase-3-like protein 1 (CHI3L1) as a crucial biomarker in liver disease is revolutionizing how clinicians approach the diagnosis, monitoring, and treatment of various liver conditions.

22 Aug 2025